---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-073838"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T06:02:07.614916+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical receives Nasdaq delisting notice for failure to meet $1 bid price rule

## Summary
- Dec 27, 2023: Nasdaq notified SeaStar it failed to regain compliance with minimum $1 bid price (Rule 5550(b)(1)).
- A Nasdaq Hearings Panel hearing is scheduled for March 12, 2024 to determine continued listing.
- Common stock (ICU) continues trading on Nasdaq Capital Market pending Panel decision.
- Company previously disclosed bid price deficiency and had until Dec 27, 2023 to cure.

## SEC filing metadata
- accession: 0000950170-23-073838
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017023073838/0000950170-23-073838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017023073838/icu-20231227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-073838
- JSON: https://secwatch.observer/filing/0000950170-23-073838.json
- Plain text: https://secwatch.observer/filing/0000950170-23-073838.txt

## Key facts
- Listing & Compliance Notices
  SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(b)(1)
  source text: December 27, 2023. On December 27, 2023, the Company received notification from the Staff that the Company had not regained compliance with the Rule (the “Delisting Notice”). This is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Company’s continued listing on The Nasdaq Capital Market, which is scheduled for Pursuant to Listing Rule 5810(d), the Company should present its views with respect to this additional deficiency at its Panel hearing to be held on March 12, 2024, as disclosed in Form 8-K Filed on Dec
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831868/000095017023073838/0000950170-23-073838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.